Identification of metabolic biomarkers and therapeutic targets in the thymoma-associated myasthenia gravis treated with methylprednisolone
Our Study reveals that TNF could serve as a potential target for methylprednisolone treatment of Thymoma-associated MG, and Cer and SM could act as potential metabolic biomarkers to assess its treatment efficacy.
Authors
- Shanshan Gu
- Guoyan Qi (ORCID: https://orcid.org/0000-0002-3119-2426)
- Yaxuan Wang
- Congya Yan
- Peng Liu (ORCID: https://orcid.org/0000-0002-1849-9634)
- Lu Liu (ORCID: https://orcid.org/0000-0001-5101-5067)
- Xiaoting Lin
- Xu Wang (ORCID: https://orcid.org/0000-0002-5854-6060)
- Li Meng (ORCID: https://orcid.org/0000-0002-3703-6168)
- Hongxia Yang
Institutions
- Hebei Medical University (CN)
- Affiliated Hospital of Taishan Medical University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1007/s12672-025-02700-2
- Citations
- 1
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- National Natural Science Foundation of China